Details for Patent: 11,344,551
✉ Email this page to a colleague
Which drugs does patent 11,344,551 protect, and when does it expire?
Patent 11,344,551 protects ORILISSA and is included in one NDA.
This patent has nine patent family members in six countries.
Summary for Patent: 11,344,551
| Title: | Methods of treating heavy menstrual bleeding |
| Abstract: | The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens. |
| Inventor(s): | Kristof Chwalisz, Laura A. Williams, Rita I. Jain, Janine D. North, Juki Wing-Keung Ng |
| Assignee: | AbbVie Inc |
| Application Number: | US16/776,230 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,344,551 |
|
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Drugs Protected by US Patent 11,344,551
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | ORILISSA | elagolix sodium | TABLET;ORAL | 210450-002 | Jul 23, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | USE OF ELAGOLIX 200 MG BID FOR 6 MONTHS TO MANAGE MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN PREMENOPAUSAL WOMEN TO REDUCE DYSMENORRHEA AND NON-MENSTRUAL PELVIC PAIN | ⤷ Start Trial | ||||
| Abbvie | ORILISSA | elagolix sodium | TABLET;ORAL | 210450-002 | Jul 23, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | USE OF ELAGOLIX 200 MG BID FOR 6 MONTHS TO MANAGE MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN PREMENOPAUSAL WOMEN HAVING DYSPAREUNIA ASSOCIATED WITH ENDOMETRIOSIS | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,344,551
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2906894 | ⤷ Start Trial | |||
| European Patent Office | 2968566 | ⤷ Start Trial | |||
| European Patent Office | 3384930 | ⤷ Start Trial | |||
| European Patent Office | 4223298 | ⤷ Start Trial | |||
| Israel | 241595 | ⤷ Start Trial | |||
| Japan | 2016513708 | ⤷ Start Trial | |||
| Japan | 6159870 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
